The role of the IGF system in cancer: From basic to clinical studies and clinical applications

Oncology

Volumn 63, Issue 4, 2002, Pages 317-332

  Moschos, Stergios J ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Epidemiology; Insulin like growth factors

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; RETINOIC ACID; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; TAMOXIFEN; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; COLON CARCINOMA; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 0036970842     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066230     Document Type: Review

References (150)

1. Holly JM, Wass JA: Insulin-like growth factors; autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments. J Endocrinol 1989;122:611-618.
2. Stewart CE, Rotwein P: Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76:1005-1026.
3. D'Ercole AJ, Stiles AD, Underwood LE: Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984;81:935-939.
4. Rosen CJ: Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications. Clin Chem 1999;45:1384-1390.
5. Schwander JC, Hauri C, Zapf J, Froesch ER: Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: Dependence on growth hormone status. Endocrinology 1983;113:297-305.
6. Tannenbaum GS, Guyda HJ, Posner BI: Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain. Science 1983;220:77-79.
7. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
8. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
9. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C: Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol 1999;17:813-817.
10. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS: Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999;17:3291-3298.
11. Allen NE, Appleby PN, Davey GK, Key TJ: Hormones and diet: Low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer 2000;83:95-97.
12. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA: IGF-I is required for normal embryonic growth in mice. Genes Dev 1993;7:2609-2617.
13. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96:7088-7092.
14. O'Dell SD, Day IN: Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998;30:767-771.
15. Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
16. Rechler MM, Brown AL: Insulin-like growth factor binding proteins: Gene structure and expression. Growth Regul 1992;2:55-68.
17. Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H: Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999;56:2076-2084.
18. Mauras N, Quarmby V, Bloedow DC: Pharmacokinetics of insulin-like growth factor I in hypopituitarism: Correlation with binding proteins. Am J Physiol 1999;277:E579-E584.
19. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA: Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res 1999;31:192-202.
20. Rajah R, Khare A, Lee PD, Cohen P: Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 1999;163:487-494.
21. Zapf J: Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol 1995;132:645-654.
22. Baxter RC: Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 1988;67:265-272.
23. Boisclair YR, Hurst KR, Ueki I, Tremblay ML, Ooi GT: Regulation and role of the acid-labile subunit of the 150-kilodalton insulin-like growth factor complex in the mouse. Pediatr Nephrol 2000;14:562-566.
24. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 1997;18:801-831.
25. Arai T, Busby W Jr, Clemmons DR: Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996;137:4571-4575.
26. Delbe J, Blat C, Desauty G, Harel L: Presence of IDF45 (mIGFBP-3) binding sites on chick embryo fibroblasts. Biochem Biophys Res Commun 1991;179:495-501.
27. Conover CA, Clarkson JT, Bale LK: Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology 1996;137:2286-2292.
28. Conover CA, Bale LK, Durham SK, Powell DR: Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology 2000;141:3098-3103.
29. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995;9:361-367.
30. Butt AJ, Firth SM, King MA, Baxter RC: Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174-39181.
31. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C: Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000;60:22-27.
32. Mira E, Manes S, Lacalle RA, Marquez G, Martinez AC: Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999;140:1657-1664.
33. Leal SM, Liu Q, Huang SS, Huang JS: The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997;272:20572-20576.
34. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y: Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999;140:1319-1328.
35. Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E: Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J 2000;14:629-640.
36. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P: Insulin-like growth factor binding protein proteases: Functional regulators of cell growth. Prog Growth Factor Res 1996;6:273-284.
37. Wolk A, Andersson SO, Mantzoros CS, Trichopoulos D, Adami HO: Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 2000;356:1902-1903.
38. Maile LA, Holly JM: Insulin-like growth factor binding protein (IGFBP) proteolysis: Occurrence, identification, role and regulation. Growth Horm IGF Res 1999;9:85-95.
39. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, Le Roith D, Pouliki V: Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 1998;58:3021-3027.
40. Werner H, Le Roith D: The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71-92.
41. Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1-6.
42. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
43. Seely BL, Reichart DR, Staubs PA, Jhun BH, Hsu D, Maegawa H, Milarski KL, Saltiel AR, Olefsky JM: Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein. J Biol Chem 1995;270:19151-19157.
44. Petley T, Graff K, Jiang W, Yang H, Florini J: Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 1999;31:70-76.
45. Rozengurt E: Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Cancer Surv 1995;24:81-96.
46. Nolan CM, Kyle JW, Watanabe H, Sly WS: Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regul 1990;1:197-213.
47. Dennis PA, Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88:580-584.
48. Kang JX, Li Y, Leaf A: Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc Natl Acad Sci USA 1997;94:13671-13676.
49. Wang ZQ, Fung MR, Barlow DP, Wagner EF: Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 1994;372:464-467.
50. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97:3455-3460.
51. Ray BS, Pearson OH: Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am 1962;12:419-433.
52. Colletti RB, Roberts JD, Devlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882-1884.
53. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
54. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517.
55. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986;46:4613-4619.
56. Pezzino V, Papa V, Milazzo G, Gliozzo B, Russo P, Scalia PL: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann NY Acad Sci 1996;784:189-201.
57. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992;22:31-38.
58. Lee AV, Darbre P, King RJ: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 1994;99:211-220.
59. Wu HK, Squire JA, Catzavelos CG, Weksberg R: Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997;235:123-129.
60. Giani C, Pinchera A, Rasmussen A, Fierabracci P, Bonacci R, Campini D, Bevilacqua G, Trock B, Lippman M E, Cullen KJ: Stromal IGF-II messenger RNA in breast cancer: Relationship with progesterone receptor expressed by malignant epithelial cells. J Endocrinol Invest 1998;21:160-165.
61. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-163.
62. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269:16433-16442.
63. Huynh H, Yang X, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-1021.
64. Stewart AJ, Johnson MD, May FE, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172-21178.
65. Richards RG, Walker MP, Sebastian J, DiAugustine RP: Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem 1998;273:11962-11969.
66. Dupont J, Karas M, Le Roith D: The potentiation of estrogen on IGF-I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000;275:35893-35901.
67. Hebert E, Herbelin C, Bougnoux P: Analysis of the IGF-II receptor gene copy number in breast carcinoma. Br J Cancer 1994;69:120-124.
68. Papa V, Constantino A, Belfiore A: Insulin receptor: What role in breast cancer? Trends Endocrinol Metab 1997;8:306-312.
69. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A: Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-1944.
70. Guvakova MA, Surmacz E: The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res 1999;251:244-255.
71. Pratt SE, Pollak MN: Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193-5198.
72. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM: Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 1999;75:652-664.
73. Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993;268:14964-14971.
74. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A: Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998;16:2459-2467.
75. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-2519.
76. Figueroa JA, Lee AV, Jackson JG, Yee D: Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995;80:3476-3482.
77. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102-1106.
78. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
79. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-1118.
80. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90:911-915.
81. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
82. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S, Fujita-Yamaguchi Y: Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998;291:469-479.
83. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB: Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1995;1:1471-1478.
84. Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
85. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP: Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-1279.
86. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL: Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997;138:1728-1735.
87. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
88. Huynh H, Seyam RM, Brock GB: Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998;58:215-218.
89. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996;81:411-420.
90. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 1996;81:3783-3792.
91. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 1999;59:2370-2375.
92. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS: Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 1999;140:2372-2381.
93. Drivdahl RH, Loop SM, Andress DL, Ostenson RC: IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995;26:72-79.
94. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-233.
95. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
96. Michell NP, Langman MJ, Eggo MC: Insulin-like growth factors and their binding proteins in human colonocytes: Preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 1997;76:60-66.
97. Jehle PM, Fussgaenger RD, Blum WF, Angelus NK, Hoeflich A, Wolf E, Jungwirth RJ: Differential autocrine regulation of intestine epithelial cell proliferation and differentiation by insulin-like growth factor (IGF) system components. Horm Metab Res 1999;31:97-102.
98. Remacle-Bonnet M, Garrouste F, el Atiq F, Marvaldi J, Pommier G: Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-6 in differentiated human colon cancer cells. J Clin Invest 1995;96:192-200.
99. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ: Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000;60:2007-2017.
100. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58:4008-4014.
101. Singh P, Rubin N: Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993;105:1218-1237.
102. Remacle-Bonnet MM, Culouscou JM, Garrouste FL, Rabenandrasana C, Marvaldi JL, Pommier GJ: Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line. J Clin Endocrinol Metab 1992;75:609-616.
103. Guo YS, Narayan S, Yallampalli C, Singh P: Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 1992;102:1101-1108.
104. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999;30:1128-1133.
105. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38:223-230.
106. Singh P, Dai B, Yallampalli C, Xu Z: Expression of IGF-II and IGF-binding proteins by colon cancer cells in relation to growth response to IGFs. Am J Physiol 1994;267:G608-G617.
107. Culouscou JM, Shoyab M: Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 1991;51:2813-2819.
108. Kim SO, Park JG, Lee YI: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996;56:3831-3836.
109. Lee YI, Lee S, Lee Y, Bong YS, Hyun SW, Yoo YD, Kim SJ, Kim YW, Poo HR: The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. Oncogene 1998;16:2367-2380.
110. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K: Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig Dis Sci 1996;41:208-215.
111. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, Le Roith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996;137:1089-1095.
112. Frankel S, Gunnell DJ, Peters TJ, Maynard M, Davey Smith G: Childhood energy intake and adult mortality from cancer: The Boyd Orr Cohort Study. BMJ 1998;316:499-504.
113. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-4672.
114. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-2734.
115. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS: Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847-853
116. Ho PJ, Baxter RC: Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997;46:333-342.
117. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP: Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001;57:471-475.
118. Khosravi J, Diamandi A, Mistry J, Scorilas A: Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001;86:694-699.
119. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-270.
120. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570-573.
121. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
122. Favoni RE, de Cupis A, Perrotta A, Sforzini S, Amoroso D, Pensa F, Miglietta L: Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: Mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol 1995;121:674-682.
123. Kaulsay KK, Ng EH, Ji CY, Ho GH, Aw TC, Lee KO: Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol 1999;140:164-168.
124. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
125. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-1350.
126. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST: High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001;88:107-113.
127. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI, Shows TB: Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986;46:6169-6173.
128. Petridou E, Dessypris N, Spanos E, Mantzoros C, Skalkidou A, Kalmanti M, Koliouskas D, Kosmidis H, Panagiotou JP, Piperopoulou F, Tzortzatou F, Trichopoulos D: Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 1999;80:494-496.
129. Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271-276.
130. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997;82:2308-2313.
131. Evans JD, Eggo MC, Donovan IA, Bramhall SR, Neoptolemos JP: Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer. Int J Pancreatol 1997;22:95-100.
132. Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS: Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. J Korean Med Sci 1997;12:32-39.
133. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C, Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000;87:118-121.
134. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999;91:151-156.
135. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401-404.
136. Mazzoccoli G, Giuliani A, Bianco G, De Cata A, Balzanelli M, Carella AM, La Viola M, Tarquini R: Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: Temporal relationship with growth hormone (GH) levels. Anticancer Res 1999;19:1397-1399.
137. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH: Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab 1993;77:199-204.
138. Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y: Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997;44:419-424.
139. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis. Science 1990;249:1007-1011.
140. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le Roith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324-7329.
141. O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL: Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413-1418.
142. Csernus VJ, Schally AV, Kiaris H, Armatis P: Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 1999;96:3098-3103.
143. Pollak M: The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med 1997;70:535-539.
144. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
145. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618.
146. Baserga R: Controlling IGF-receptor function: A possible strategy for tumor therapy. Trends Biotechnol 1996;14:150-152.
147. Konety BR, Johnson CS, Trump DL, Getzenberg RH: Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 1999;17:77-84.
148. Miller WH Jr: The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998;83:1471-1482.
149. Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ, Burghouts JT, van der Linden GH, Klijn JG: Feasibility, endocrine and
150. Ritzen EM: Does growth hormone increase the risk of malignancies? Horm Res 1993;39:99-101.